Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with regard to its clinical course. The limitations of the methods currently available for prognostic assessment in CLL do not allow accurate prediction of the risk of disease progression in individual patients. The recently developed cDNA array technique provides a unique opportunity to study gene expression in various malignancies. To identify new molecular markers for prognostication of CLL patients, we analyzed cDNA arrays by using hierarchical clustering and standard statistic t-test on 34 CLL patients. We found significant expression differences in 78 genes compared to the reference tonsillar B lymphocytes. A cluster of genes, LCP1, PARP, BLR1, DEK, NPM, MCL1, SLP76, STAM, HIVEP1, EVI2B, CD25, HTLF, HIVEP2, BCL2, MNDA, PBX3, EBI2, TCF1, CGRP, CD14, IL8, GZMK, GPR17 and CD79B, was associated (P Ͻ 0.05) with the unfavorable 11q deletion and also with the unfavorable Binet stages B and C. We present here gene expression profiling that is associated with CLL patients with the 11q23 deletion. Many of the genes in the cluster have not previously been shown to be related to the initiation or progression of CLL. These novel findings provide fundamental information for further attempts to understand the interaction of the clustered genes in the leukomogenesis of CLL in order to better design treatments aimed at specific molecular target(s). Leukemia (2001) 15, 1721-1728.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world. The prognosis for patients with CLL is highly variable. Some patients survive with indolent disease for many years without any treatment and eventually succumb to other diseases. Other patients develop a more aggressive malignancy from which they die. The median survival is approximately 10 years. 1 In order to reduce CLL-related mortality, it is essential to identify patients at risk and prevent progression of their disease. Cytogenetic studies have shown chromosome aberrations in 50-80% of CLL patients and certain genetic changes have been reported repeatedly, such as trisomy 12, deletions in 13q and 14q, and losses in 6q, 11q and 13q. [2] [3] [4] [5] [6] [7] Losses in 11q appear to be one of the most common structural chromosome aberrations in CLL and they are associated with both the development of the disease and survival. 3, 4, [7] [8] [9] Despite the relatively large number of patients available for study, little is known about the genes involved in the etiology and progression of CLL.
cDNA microarray is a new powerful technology capable of profiling the gene expression patterns of hundreds to thou-sands of genes in a single experiment. The information obtained from cDNA array analyses provides new diagnostic and prognostic parameters for cancer patients. 10, 11 We used this technology to investigate the gene expression profiles of patients at different stages of CLL and to assess the association between the gene expression profile and the clinical behavior of the disease.
Materials and methods

Patients
Peripheral blood specimens were collected from 34 CLL patients referred to the CLL outpatient clinic at the Tampere University Hospital. The selection criterion was a blood lymphocyte count of 30 × 10 9 or higher. 1 The median age of the patients (nine females and 25 males) was 64.8 years (range 48-79). The patients were diagnosed and staged according to standard clinical, morphological and immunophenotyping criteria and the Binet system. 1, 12, 13 All patients had a CD19 1 The clinical data are shown in Table 1 .
Reference
To obtain pure reference material for the expression comparison, CD19-positive B cells were purified from human adenoid palatine tonsil samples from six healthy children. The B cells were purified using microbeads conjugated to a monoclonal CD19 antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). The proportion of T lymphocytes was less than 5%, indicating that 95% of the isolated cells represented B-lymphocyte population.
RNA isolation
Lymphocytic cells were isolated from the patient's blood using one-step density gradient centrifugation in Ficoll-Paque (Pharmacia Fine Chemicals, Uppsala, Sweden), and the total RNA was extracted using the Trizol Reagent (Gibco BRL, Grand Island, NY, USA). The proportion of monocytes and polyclonal T and B lymphocytes was 1-13%, indicating that 87-99% of the isolated cells represented the leukemic population. The RNA was then treated with DNase I (Boehringer Mannheim, Mannheim, Germany) for purification, according to the protocol of the Atlas cDNA Expression Array's user manual (Clontech Laboratories, Palo Alto, CA, USA). The quality and integrity of the RNA were checked using 1% aga- 
cDNA array hybridization
To screen the samples for gene expression, we used the Atlas Human Hematology array (Clontech; 7737-1). Each filter contains 406 duplicate spots representing cDNAs of known and sequence-verified genes (for information about genes see www.clontech.com). The total RNA (3-4 g) from 34 CLL patients and from reference, CD19-positive B cells purified human adenoid palatine tonsil samples, was converted into cDNA and labeled with 33 PdATP using the Clontech cDNA array labeling kit. After hybridization, the filters were washed following the manufacturer's instructions. The filters were exposed to imaging plates (BAS-MP 2040S; Fuji, Kanagawa, Japan) and scanned with a phosphorimager (Bio-Imaging Analyzer, BAS-2500; Fuji) to obtain high-resolution (16 bit) tiffformat images.
cDNA array data analysis
The intensity ratio was quantified for each gene and it reflected the relative abundance of the gene in each experimental RNA sample compared with RNA samples pooled from six adenoids. The intensities of spots were obtained with Atlas Image analysis software (Clontech). Local background was subtracted at each point. To minimize the possible effect of differences in the amounts of RNA and efficiencies in the hybridizations, intensities were normalized so that the sums of intensities between patients were equal. To obtain the ratio value of expression, intensity values of genes from each patient were compared to values from reference sample. Ratios were log 2 transformed and genes, in which the expression ratio altered significantly in at least three patients, were taken to further analysis. Hierarchical clustering was applied to both axes with the Cluster program (Michael Eisen, Stanford University, USA) using uncentered correlation as a similarity metric. Results were visualized with the TreeView program (Michael Eisen, Stanford University). To identify the subsets of genes that may be associated with a poor clinical outcome in patients with CLL, the Mann-Whitney U test was used to compare the differences in gene expression between different groups. Statistical analyses were performed using the SPSS statistical package (SPSS, Chicago, IL, USA). The statistical significance was accepted when P Ͻ 0.05.
Thresholds and controls for cDNA array analysis
All the filters used were from same printing batch to minimize variation from one lot to another. To ensure the optimum quality of the hybridizations, the filters were used for a maximum of three times. Five samples were hybridized twice, each in a different filter in a different experiment, to confirm the reproducibility of the results. The two independent hybridization images of the same sample were then compared to each other using Atlas Image software (Clontech). In our analysis, the differences between any two hybridizations obtained from the same sample were less than 2% using a ratio of 1.5 for overexpression and 0.65 for underexpression, and less than 1% using a ratio of 2.0 for overexpression and Leukemia 0.5 for underexpression. We raised the threshold ratio values to 3 for overexpression and to 0.33 for underexpression.
Real-time quantitative reverse transcription polymerase chain reaction (QRT-PCR)
Quantitative RT-PCR was performed to confirm the expression alteration of seven genes (MCL1, BAX, BCL2L1, EVI2B, SLP76, HIVEP1 and BCL2). The First Strand cDNA Synthesis Kit for RT-PCR (Roche Diagnostic, Mannheim, Germany) was used to obtain cDNAs from 30 CLL samples and from reference B cells applying random hexamer primers. Gene-specific PCR primer sequence information corresponding to the PCR targets on the Atlas Human Hematology/Immunology cDNA expression array filters (Clontech) was acquired from TIB MOLBIOL Syntheselabor (Berlin, Germany). Primers for the following genes were used, MCL1, BAX, BCL2L1, EVI2B, SLP76, HIVEP1 and BCL2 (Table 2) . PCRs were performed in the LightCycler thermal cycler (Roche). Standard curves were obtained by using serial dilutions of the ␤-globulin gene (DNA Control kit; Roche) according to the supplier's instructions in each LightCycler run. The PCR reaction consisted of 2 l of DNA Master SYBR Green I mix (LightCycler-FastStart DNA Master SYBR Green I kit, Roche; containing Taq DNA polymerase, dNTP, MgCl 2 , and SYBR Green I dye), 2 l of cDNA and 4-10 pmol of each primer. The amplification program included an initial denaturation at 95°C with 8 min hold, followed by 45 cycles at 95°C with 10 s hold, annealing temperature of 60°C with 5 s hold, and at 72°C with 20 s hold. Amplifications were followed by melting curve analysis using the program run for one cycle at 95°C with 0 s hold, 65°C with 10 s hold, and 95°C with 0 s hold at the acquisition step mode. A negative control without cDNA template was run simultaneously with every assay. Each PCR from each cDNA sample was run in duplicate. The concentration of each gene product was determined on the basis of kinetic approach using the LightCycler software (Roche). Results are expressed as ratio value of expression obtained from comparison of the concentration values of genes from each patient with the average value of expression from reference sample.
Detection of 11q23 deletion by fluorescence in situ hybridization
YAC clone from DEPH-Généthon (Paris, France) was labeled and applied for the analysis of 11q23 deletion as described earlier.
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Results
The analysis revealed 78 genes that were differentially expressed as compared to the gene expression profile of the reference pool sample, in at least three of the cases. Of the differentially expressed genes, 37 were down-regulated and 41 were up-regulated. These genes included surface antigens, transcription factors, oncogenes and protein kinases, chemokines and chemokine receptors, and other genes involved in blood disorders. The profiles for all the patients are shown in Figure 1 , in which a hierarchical clustering was used to group the genes on the basis of the similarity in their expression. The same clustering method was also used to group the 34 patient samples on the basis of similarities in their expression of these genes. Although no information on the identity of the sample was used in the clustering, the algorithm segregated all the patients with 11q deletion into the same class. However, the algorithm failed to aggregate the patients in stages A, B and C into definite classes. To identify a subgroup of genes that may be associated with poor clinical outcome in CLL patients, we performed standard statistics (t-test) to compare the gene expression levels in the different groups. The expression of eight down-regulated genes, LCP1, PARP, BLR1, DEK, NPM and MCL1, was significantly different between the groups with and without 11q23 deletion (P Ͻ 0.05), whereas the expression of BLR1 and EBI2 differed between stage B or C disease and stage A disease (P Ͻ 0.05) (Figure 1 ). Ten genes, SLP76, STAM, HIVEP1, EVI2B, CD25, HTLF, HIVEP2, BCL2, MNDA and PBX3, were more frequently up-regulated in patients with 11q23 deletion than in those without the deletion (P Ͻ 0.05). The expression of TCF1, CGRP, CD14, IL8, and GZMK was significantly higher in stage B or C disease than in stage A disease (P Ͻ 0.05). The expression of CD79B, TCF1, CD14, GPR17 and GZMK associated with the disease progression (P Ͻ 0.05) (Figure 1) .
We used quantitative RT-PCR to validate the expression differences for seven genes. Relative expression levels initially determined with the cDNA array were correlated with LightCycler results for 30 samples tested (lack of sufficient RNA prevented testing of four cases). Figure 2 illustrates the concordant results by cDNA array and LightCycler.
Discussion
We used a cDNA array to profile gene expression in CLL patients with different stages/status. Our results show that all the patients with 11q deletion segregated into the same class based on global similarities in gene expression patterns. The clustering of the patients based on their expression signatures did not correlate with their Binet classification. This finding further supports the notion that CLL characterized by 11q deletion defines a distinct disease subgroup and the clinical heterogeneity of CLL is due to unrecognized molecular heterogeneity of CLL in the patients. Another finding of this study is that subsets of genes can be identified using standard statistics, the t-test. These subsets can be used for grouping and indicating a poor prognosis. Our results also show that patients with poor prognostic parameters expressed a higher number of disease-related genes than patients with a more favorable prognosis. This may indicate that increased gene expression is the underlying mechanism of CLL progression.
CD19-positive B cells were pooled from six normal adenoids and used as reference material. The following issues were taken into consideration when interpreting the over-and Several up-regulated and down-regulated genes were commonly expressed in most CLL patients irrespective of the Binet stage or the 11q status. These up-regulated genes are surface antigens CD5, CD23, CD55 and CD44H, oncogenes AF17 and ZAP70, B cell-specific activator protein PAX5, and P1. Down-regulated genes are CD21, CD22, CD10, CD54, RGS, RHOM2, TOP2A, AHPD1, ADA and RAC1. These genes are probably not related to CLL progression but may be more important for the initiation of this disease or may reflect lineage specificity (as discussed under Results).
Loss of genomic material in 11q is one of the most common structural chromosome aberrations in CLL and the finding is associated with disease progression and poor survival. 3, 4, [7] [8] [9] Our results showed that gene expression in patients with 11q23 deletions, observed by high-resolution FISH mapping, irrespective of their Binet clinical stage, varied in a larger number of genes than in other patients. Sixteen genes had statistically significant differences in expression between the patients with 11q23 deletion and without it. Of these genes, 10 were up-regulated and six down-regulated. Among the down-regulated genes, apoptosis-associated proteins MCL1 and PARP, and oncogenes DEK and NPM showed significantly higher average values in expression in patients with 11q23 deletion than in patients without 11q23 deletion, whereas the value of cell surface antigen BLR1 was significantly lower in the presence of 11q deletion. These genes together with 10 up-regulated genes, SLP76, STAM, HIVEP1, EVI2B, CD25, HTLF, HIVEP2, BCl2, MNDA and PBX3, indicated that 11q23 deletion is associated with the activation of a number of genes. The significantly higher level of expression in a number of genes in these patients may contribute to the pathogenesis of the CLL subgroup characterized by 11q23 deletion and poor prognosis. Conceivably, we suggest that the loss of putative tumor suppression genes in the 11q23 deletion represents a general removal of suppression that leads to activation of several cellular pathways in CLL.
Overexpression of STAM and SLP76 was significant in all patients with 11q23 deletion. STAM and SLP76 both act as adaptor molecules and are involved in intracellular signal transduction mediated by a variety of cytokines. STAM has been implicated in the signaling pathways for cell growth and c-myc induction. 15 The role of STAM in CLL, as well as in other types of hematological malignancy, is unknown. Another adaptor protein SLP76 is normally expressed in T lymphocytes and myeloid cells, and it is a substrate for ZAP70. It has been reported that the SLP76 protein was not detected in a number of B cell lines or in normal mouse B cells. 16 The involvement of SLP76 has been limited to T cell development. 17 Overexpression of EVI2B in the patients with 11q23 deletion was more frequent than in the patients without 11q23 deletion. The possible role of DNA viruses, such as ecotropic viruses, in the development of CLL, is unknown. However, it has been suggested that the Epstein-Barr virus affects blast and growth transformation in infected B lymphocytes and the progression of CLL/small lymphocytic lymphoma to Hodgkin-like lymphoma. 18, 19 EBI2B lies within an intron of the neurofibromatosis type 1 tumor suppressor gene and is expressed in a number of different cell types, including myeloid cells. 20, 21 EVI2B is also located within EVI2, a common viral integration site identified in retrovirus-induced myeloid tumors. 22 It has been speculated that viral integration at EVI2 alters the expression of EVI2B and that this altered expression predisposes mice to myeloid tumor development. 20, 22 Furthermore, human T cell leukemia virus enhancer factor (HTLF) and human immunodeficiency virus type I enhancer-binding proteins 1 and 2 (HIVEP1 and HIVEP2) were frequently up-regulated in patients with 11q23 deletion. Whether DNA viruses are involved in the development of CLL patients with 11q deletion is an issue that has to be further studied.
Apoptosis dysregulation is a major feature of CLL. 23 According to the role of BCL2, increased expression of the bcl-2 protein is regarded as a major mechanism in the genesis of CLL. High-level overexpression of BCL2 was found in our patients with 11q23 deletion. MNDA and PBX3, both involved in transcription and act as transcription activators, were also frequently seen in the patients with 11q23 deletion. MNDA is a nuclear antigen expressed specifically in maturing cells of the myelomonocytic lineage and in monocytes and granulocytes. Examination of lymphoid tissues showed a low level of expression in a population of normal mantle B lymphocytes and in a subset of B cell neoplasms including small lymphocytic lymphoma. 24 MNDA is considered an interferoninducible gene, participating in blood cell-specific responses to interferons. 25 When we compared the gene expression in the Binet clinical staging groups A, B and C, we found that two down-regulated genes, BLR1 and EBI2, and five up-regulated genes, TCF1, CGRP, CD14, IL8 and GZMK, displayed statistically significant differences in expression between stage A and stage B or stage C (P Ͻ 0.05). Furthermore, three out of the five above-mentioned up-regulated genes, TCF1, CD14, GZMK together with CD79B and GPR17, were associated with fast lymphocyte doubling time (P Ͻ 0.05). This makes these genes particularly interesting because they may be related to CLL progression and could subsequently be useful as prognostic markers for CLL patients. Of these up-regulated genes, cell surface antigen CD14 has been demonstrated to be associated with more advanced B-CLL patients and shorter overall survival. 26 CGRP is a sensory neuropeptide with inflammatory and immunoregulatory activities. CGRP played an inhibitory role in early B cell differentiation 27 and inhibited interleukin-7-induced pre-B cell colony formation. 28 Interleukin-8 (IL-8) has been shown to induce the accumulation of B cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. 29 The role of GRP17, a potential chemokine receptor, in CLL is not known. The level of CD79 expression was significantly higher in the group of fast disease progression. This result is consistent with an immunohistochemical study on CLL cases in which the advanced clinical stage (Binet stages B and C) was most frequently observed in CD79b + cases than in CD79b − cases. 30 Two down-regulated genes, BLR1 and EBI2 that encode G protein-coupled receptors, have been suggested to have a role in B cell migration or normal lymphocyte functions. 31, 32 Our study was not designed to evaluate the prognostic value of the findings. For this purpose a larger number of patients and longer follow-up period are needed. In a recent report Stratowa et al 33 were able to identify genes that indicate poor prognosis. Many of the genes encode cell adhesion-associated molecules (L-selectin, integrin-B2, ILIB, IL8 and EGRI). In their comprehensive study, Stratowa et al analyzed the expression levels of 1024 selected genes in 54 CLL cases. They did not find correlation between the gene expression profiles and the 11q23 deletion. Different gene selections in the arrays may partly explain why our findings are not in line with theirs.
To conclude, our most prominent findings are significant differences in the gene expression profiles of patients with indicators of poor prognosis (stages B and C, or 11q deletion). These differences point to several genes that could be utilized for prognostication of CLL patients. The genes that were commonly expressed in patients irrespective of their ABC stage or chromosomal aberration are probably related to the initiation of CLL. Our novel results are the first milestone on the road to finding molecular prognostic markers for CLL. Further study should be carried out in a larger patient material to ascertain whether gene expression clustering can reveal molecular prognostic markers in CLL.
